Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Breast Cancer Research and Treatment

Volumn 123, Issue 3, 2010, Pages 785-793

  Svensson, Helene ^a,b   Einbeigi, Zakaria ^b   Johansson, Hemming ^c   Hatschek, Thomas ^d   Brandberg, Yvonne ^a  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chemotherapy; EORTC QLQ BR23; EORTC QLQ C 30; Health related quality of life; Metastatic breast cancer

Indexed keywords

CAPECITABINE; EPIRUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ADULT; AGED; BREAST METASTASIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EMOTIONALITY; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE BREAST CANCER MODULE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE C30; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOCIAL INTERACTION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; EMOTION; FEMALE; METASTASIS; MIDDLE AGED; PSYCHOLOGICAL ASPECT; REGRESSION ANALYSIS; SOCIAL BEHAVIOR; SWEDEN; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DYSPNEA; EMOTIONS; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOCIAL BEHAVIOR; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952115527     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1084-8     Document Type: Review

References (20)

1. Young T, De Haes J, Curran D (1999) Collecting quality of life data in EORTC clinical trials-what happens in practice? Guidelines for assessing quality of life in EORTC clinical trials (internal report). Brussels, EORTC
2. De Haes J, Curran D, Young T et al (1999) Quality of life evaluation in oncological clinical trials-The EORTC model The EORTC quality of life study group. Psychooncology 8(3):260-263
3. Bottomely A, Biganzoli L, Cufer T et al (2004) Randomized controlled trial investigated short-Term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosfamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, investigational drug branch for breast cancer and the new drug development group study. J Clin Oncol 22(13):2576-2586 (Pubitemid 41103744)
4. Efficace F, Biganzoli L, Piccart M et al (2004) Baseline healthrelated quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40(7):1021-1030 (Pubitemid 38496258)
5. Cassier PA, Chabaud S, Trillet-Lenoir V et al (2008) A phase III trial of doxorubicin and dosetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: result of the Erasme 3 study. Breast Cancer Res Treat 109(2):343-350 (Pubitemid 351658936)
6. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365-376 (Pubitemid 23073154)
7. Sprangers MAD, Groenvold M, Arraras JI et al (1996) The EORTC breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14:2756-2768 (Pubitemid 26329662)
8. Fayers PM, Aaronson NK, Bjordal K et al (2001) On behalf of the EORTC quality of life group EORTC QLQ-C30 scoring manual, 3rd edn. EORTC, Brussels
9. Michelsson H, Bolund C, Nilssson B, Brandberg Y (2000) Health-related quality of life measured by the EORTC QLQ-C30. Reference values from a large sample of the swedish population. Acta Oncologica 39(4):477-484
10. Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139-144 (Pubitemid 28041591)
11. Kramer JA, Curran D, Piccart M et al (2000) Randomized trial of paclitaxel versus doxorubicin as first line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. Eur J Cancer 36(12):1488-1497 (Pubitemid 30619001)
12. Riccardi A, Tinelli C, Brugnatelli S et al (2000) Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: A prospective randomizes multicentric study on antitumor effect and quality of life in advanced breast cancer. Int J Oncol 16(4):769-776
13. Hakamies-Blomqvist L, Luoma M, Sjöström J et al (2000) Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group. Eur J Cancer 36(11):1411-1417 (Pubitemid 30421146)
14. Jassem J, Pienkowski T, Pluzanska A et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19(6):1707-1715 (Pubitemid 32230871)
15. Botenbal M, Creemers GJ, Braun HJ et al (2005) Phase II to III study comparing doxorubicin and dosetaxel with fluorouracil, doxorubicin and cyclophosphamide as first line chemotherapy in patients with metastatic breast cancer: results of Dutch community setting trial for the clinical trial group of the comprehensive cancer centre. J Clin Oncol 23(28):17081-17088
16. Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17(8):2341-2354 (Pubitemid 29368232)
17. Norris B, Pritchard KI, James K et al (2000) Phase III comparative study of Vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National cancer institute of Canada clinical trials group study MA8. J Clin Oncol 18(12):2385-2394 (Pubitemid 30415825)
18. Brandberg Y, Michelson H, Nilsson B et al (2003) Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported highdose chemotherapy with cyclophosphamide, thiotepa, carboplatin or tailored therapy with fluorouracil, epirubicin, cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol 21(19):3659-3664 (Pubitemid 46594060)
19. Bang SM, Park SH, Kang HG et al (2005) Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer 13(7):515-521
20. Mayer EL, Burstein HJ (2007) Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North am 21(2):257-272 (Pubitemid 46754731)